Immune Thrombocytopenia (ITP) Market

1. Immune Thrombocytopenia (ITP) Market DelveInsight’s ‘Immune Thrombocytopenia Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the ITP, historical and forecasted epidemiology as well as the ITP market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan. Geography Covered • The United States • EU5 (Germany, France, Italy, Spain, and the United Kingdom) • Japan Study Period: 2017–2030 View report: https://www.delveinsight.com/sample-request/immune-thrombocytopenia-market Immune Thrombocytopenia (ITP) Disease Understanding Immune Thrombocytopenia (ITP) Overview Immune Thrombocytopenia (ITP), previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its platelets and destroys them too quickly. ITP is a disorder that affects the overall number of blood platelets rather than their function. Many of the symptoms of ITP stem from a low platelet count leading to excessive bleeding. In severe cases, frequent bleeding episodes may result in low levels of circulating red blood cells (anemia), which may cause fatigue and impair response to exertion. In rare cases, serious bleeding into the brain (intracranial hemorrhage) may occur. The two main types of ITP are acute (short term) and chronic (long term). ITP is also categorized as primary and secondary based on the cause of the disease. ITP in the absence of other causes or disorders that may be associated with the thrombocytopenia is known as primary ITP, whereas, secondary ITP refers to immune-mediated thrombocytopenia with an underlying cause, including drug-induced, or associated with systemic illness (e.g., systemic lupus erythematosus, infection [e.g., HIV], immune deficiency [e.g., common lymphoproliferative syndrome], and other causes). variable immunodeficiency or autoimmune

2. Immune Thrombocytopenia (ITP) Epidemiology The Immune Thrombocytopenia epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of ITP, Total Diagnosed Prevalent Population of ITP, and Gender-specific Diagnosed Prevalent Population of ITP scenario of ITP in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030. Key Findings  Assessments as per DelveInsight’s analysts show that the majority of cases of ITP are females as compared to males. There was a total of 32,364 female and 20,998 male diagnosed cases of ITP in 2017 in the United States.  DelveInsight’s estimations suggest that the total prevalent population ITP in the seven major markets was approximately 180,498 in 2017. The total diagnosed prevalent cases in the 7MM was estimated to be approximately 147,174 in 2017.  Immune Thrombocytopenia (ITP) Epidemiology The epidemiology segment also provides the ITP epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan. Download our free report: https://www.delveinsight.com/sample-request/immune- thrombocytopenia-market Immune Thrombocytopenia (ITP) Drug Chapters The drug chapter segment of the ITP report encloses the detailed analysis of Immune Throbocytopenia marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the ITP clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases. Immune Thrombocytopenia (ITP) Marketed Drugs Tavalisse (fostamatinib disodium hexahydrate): Rigel Pharmaceuticals Fostamatinib disodium (also known as Tavalisse; R-985788) is an orally-bioavailable investigational agent being developed by Rigel pharmaceuticals and approved for the treatment of patients suffering from persistent/chronic adult idiopathic thrombocytopenic purpura. The therapeutic candidate inhibits FcR-triggered, Syk-dependent cytoskeletal rearrangement during phagocytosis. As stated by Rigel Pharmaceuticals, fostamatinib has a unique mechanism of action, blocking IgG receptor signaling in both macrophages and B cells via SYK kinase. The company is focusing on the fostamatinib ITP program specifically on the chronic form of this disease targeting the underlying autoimmune cause of the disease rather than stimulating platelet production. Moreover, fostamatinib is also being evaluated for autoimmune hemolytic anemia, IgA nephropathy, graft-versus-host disease, and ovarian cancer. In June 2017, the company filed for the New Drug Application to the USFDA for the use of fostamatinib in chronic ITP patients. Later in October 2017, Rigel Pharmaceuticals indicated that the FDA anticipated the Prescription Drug User Fee Act (PDUFA) action date for the application review in April 2018. And in April 2018, Tavalisse got approved for the treatment of Idiopathic Thrombocytopenic Purpura.

3. Products detail in the report… List to be continued in the report… Immune Thrombocytopenia (ITP) Emerging Drugs BT-595: Biotest BT-595 (IgG Next Generation) is an intravenously administered, novel polyvalent immunoglobulins (IVIG) designed specifically to treat primary immune deficiencies, secondary antibody deficiency syndromes, and several autoimmune disorders. Currently, the company is developing this therapeutic molecule in the Phase III stage of development for the treatment of patients with Immune Thrombocytopenic Purpura (ITP). Products detail in the report… Immune Thrombocytopenia (ITP) Market Outlook The US Food and Drug Administration (FDA) has approved three Thrombopoietin receptor agonist (TPO-RA) therapies: romiplostim (Nplate), eltrombopag (Promacta), and avatrombopag (Doptelet). For Europe and Japan, only two TPO-RAs is approved, i.e., Nplate and Promacta. Promacta and Nplate will lose their patent in 2022 in the US, whereas, in Europe and Japan, Nplate loses the patent in 2019 and Promacta will lose patent in 2025. Due to their patent expiry, it is expected that the approval of Doptelet is likely to cover a major patient pool. At present, there have been few well-designed randomized trials targeted at reducing chronic ITP in adults and children. Further prospective trials may be able to enhance the approach and improve overall outcomes. Adequate long-term follow-up will be necessary to determine whether relapse is truly averted or simply delayed. It will also be important to select novel composite outcomes that account for clinical events as well as evaluate the cost and the added adverse events of combined therapies. In addition to clinical trials, essential research should focus on identifying patients who would benefit from more intensive therapy: for example, the ability to determine those patients who will develop persistent or chronic ITP or identification of markers predictive of who would benefit most from a specific therapy. According to DelveInsight, ITP 7MM is expected to change in the study period 2017–2030. Key Findings  The Immune Thrombocytopenia market size in the 7MM was found to be USD 2,527.72 million in 2017. The United States accounts for the highest market size of Immune Thrombocytopenia (ITP), in comparison to the other major markets i.e., EU5 countries, and Japan  Request for sample pages of the report, Immune Thrombocytopenia (ITP) Market Outlook: https://www.delveinsight.com/sample-request/immune-thrombocytopenia-market report@ Download thrombocytopenia-market our full https://www.delveinsight.com/report-store/immune-